Prabir Roy-Chaudhury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Prabir Roy-Chaudhury has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Burnett S. Kelly
Department of Surgery, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
3 shared publicationsJianhua Zhang
Division of Nephrology and Hypertension, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
3 shared publicationsMurad Melhem
Department of Pathology, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
3 shared publicationsPankaj Desai
Department of Surgery, University of Cincinnati Medical Center, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
3 shared publicationsRino Munda
Department of Surgery University of Cincinnati Cincinnati Ohio
3 shared publicationsSue C. Heffelfinger
College of Pharmacy, University of Cincinnati, 136 E Health Professions Building, Cincinnati, OH 45267-0004, USA
3 shared publications
Latest Publications
- 28 May 2014
- Published by Wiley in Seminars in Dialysis
- Vol. 27 (6) , 626-632
Proliferation Patterns in a Pig Model of AV Fistula Stenosis: Can we Translate Biology into Novel Therapies?
Arteriovenous fistula (AVF) stenosis remains an important cause of AVF maturation failure for which there are currently no effective therapies. To understand the mechanisms involved, we have examined the pattern of cellular proliferation at different time points in a pig model of AVF stenosis. Immunohistochemical analysis of cellular proliferation was performed at 2, 7, 28, and 42 days. The distribution of cellular proliferation within the different layers of the vessel wall was also studied. An ANOVA analysis was used to identify differences between the magnitude of cellular proliferation at different time points and within different layers of the vessel wall. Adventitial proliferation occurred at 2 days and declined over time. Intimal and medial proliferation peaked at 7 days and then decreased over time. There was minimal proliferation in all three layers at the 28‐ and 42‐day time points. An important finding was the presence of active myofibroblast proliferation within “neointimal buds” at the 7‐day time point. Results suggest that there could be early adventitial activation, followed by a passage of these cells into the medial and intimal layers. These suggest that the application of perivascular antiproliferative (adventitial) therapies at the time of surgery could potentially reduce AVF maturation failure.
- 28 May 2014
- Published by Wiley in Seminars in Dialysis
- Vol. 27 (6) , 626-632
Proliferation Patterns in a Pig Model of AV Fistula Stenosis: Can we Translate Biology into Novel Therapies?
Arteriovenous fistula (AVF) stenosis remains an important cause of AVF maturation failure for which there are currently no effective therapies. To understand the mechanisms involved, we have examined the pattern of cellular proliferation at different time points in a pig model of AVF stenosis. Immunohistochemical analysis of cellular proliferation was performed at 2, 7, 28, and 42 days. The distribution of cellular proliferation within the different layers of the vessel wall was also studied. An ANOVA analysis was used to identify differences between the magnitude of cellular proliferation at different time points and within different layers of the vessel wall. Adventitial proliferation occurred at 2 days and declined over time. Intimal and medial proliferation peaked at 7 days and then decreased over time. There was minimal proliferation in all three layers at the 28‐ and 42‐day time points. An important finding was the presence of active myofibroblast proliferation within “neointimal buds” at the 7‐day time point. Results suggest that there could be early adventitial activation, followed by a passage of these cells into the medial and intimal layers. These suggest that the application of perivascular antiproliferative (adventitial) therapies at the time of surgery could potentially reduce AVF maturation failure.
- 4 April 2012
- Published by Wiley in Seminars in Dialysis
- Vol. 26 (1) , 97-99
Arteriovenous Fistula Creation Using the Optiflow Vascular Anastomosis Device: A First in Man Pilot Study
Although arteriovenous fistulae are the preferred form of dialysis vascular access they continue to have significant problems with maturation failure. The Optiflow device is a sutureless anastomotic conduit which could potentially reduce surgical time and also standardize the surgical procedure. We report herein on the “First in Man” experience with the Optiflow device.
- 4 April 2012
- Published by Wiley in Seminars in Dialysis
- Vol. 26 (1) , 97-99
Arteriovenous Fistula Creation Using the Optiflow Vascular Anastomosis Device: A First in Man Pilot Study
Although arteriovenous fistulae are the preferred form of dialysis vascular access they continue to have significant problems with maturation failure. The Optiflow device is a sutureless anastomotic conduit which could potentially reduce surgical time and also standardize the surgical procedure. We report herein on the “First in Man” experience with the Optiflow device.
- Open Access
- 1 March 2012
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 7 (3) , 521-524
Academic Interventional Nephrology
Summary: Dialysis vascular access dysfunction is currently a huge clinical problem. We believe that comprehensive academic-based dialysis vascular access programs that go all the way from basic and translational science investigation to clinical research to a dedicated curriculum and opportunities in vascular access for nephrologists in training are essential for improving dialysis vascular access care. This paper reviews the fundamental concepts and requirements for us to move toward this vision.
- 1 March 2012
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 7 (3) , 521-524
Open AccessAcademic Interventional Nephrology
Summary: Dialysis vascular access dysfunction is currently a huge clinical problem. We believe that comprehensive academic-based dialysis vascular access programs that go all the way from basic and translational science investigation to clinical research to a dedicated curriculum and opportunities in vascular access for nephrologists in training are essential for improving dialysis vascular access care. This paper reviews the fundamental concepts and requirements for us to move toward this vision.
- 20 November 2007
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 4 (2) , 74-75
Utility of formaldehyde-fixed arterial allografts for hemodialysis access
- 20 November 2007
- Published by Springer Nature in Nature Clinical Practice Nephrology
- Vol. 4 (2) , 74-75
Utility of formaldehyde-fixed arterial allografts for hemodialysis access
- 1 August 2005
- Published by Elsevier in Cardiology Clinics
- Vol. 23 (3) , 249-273
Vascular Access in Hemodialysis: Issues, Management, and Emerging Concepts
- 1 August 2005
- Published by Elsevier in Cardiology Clinics
- Vol. 23 (3) , 249-273
Vascular Access in Hemodialysis: Issues, Management, and Emerging Concepts
- 1 December 2004
- Published by S. Karger AG in Blood Purification
- Vol. 23 (1) , 29-35
Novel Therapies for Hemodialysis Vascular Access Dysfunction: Fact or Fiction!
Hemodialysis vascular access dysfunction is a major cause of morbidity in the hemodialysis population and contributes significantly to the overall cost of end-stage renal disease programs. At a histological level, most hemodialysis vascular access dysfunction (in both native arteriovenous fistulae and PTFE dialysis access grafts) is due to venous stenosis and thrombosis, secondary to venous neointimal hyperplasia. However, despite a wealth of experimental and clinical data on the use of novel therapeutic interventions that target neointimal hyperplasia in the setting of coronary artery disease, there are unfortunately no effective therapeutic interventions for hemodialysis vascular access dysfunction at the present time. This is particularly unfortunate, since neointimal hyperplasia in the setting of hemodialysis vascular access fistulae and grafts could be the ideal clinical model to test novel therapeutic interventions for neointimal hyperplasia.
- 1 December 2004
- Published by S. Karger AG in Blood Purification
- Vol. 23 (1) , 29-35
Novel Therapies for Hemodialysis Vascular Access Dysfunction: Fact or Fiction!
Hemodialysis vascular access dysfunction is a major cause of morbidity in the hemodialysis population and contributes significantly to the overall cost of end-stage renal disease programs. At a histological level, most hemodialysis vascular access dysfunction (in both native arteriovenous fistulae and PTFE dialysis access grafts) is due to venous stenosis and thrombosis, secondary to venous neointimal hyperplasia. However, despite a wealth of experimental and clinical data on the use of novel therapeutic interventions that target neointimal hyperplasia in the setting of coronary artery disease, there are unfortunately no effective therapeutic interventions for hemodialysis vascular access dysfunction at the present time. This is particularly unfortunate, since neointimal hyperplasia in the setting of hemodialysis vascular access fistulae and grafts could be the ideal clinical model to test novel therapeutic interventions for neointimal hyperplasia.
- 22 January 2003
- Published by S. Karger AG in Blood Purification
- Vol. 21 (1) , 99-110
Hemodialysis Vascular Access Dysfunction: From Pathophysiology to Novel Therapies
Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis population at a cost of over USD 1 billion per annum. Most hemodialysis grafts fail due to a venous stenosis (venous neointimal hyperplasia) which then results in thrombosis of the graft. Despite the magnitude of the clinical problem there are currently no effective therapies for this condition. The current review (a) describes the pathogenesis and pathology of venous stenosis in dialysis access grafts and (b) discusses the development and application of novel therapeutic interventions for this difficult clinical problem. Special emphasis is laid on the fact that PTFE dialysis access grafts could be the ideal clinical model for testing out novel local therapies to block neointimal hyperplasia.
- 22 January 2003
- Published by S. Karger AG in Blood Purification
- Vol. 21 (1) , 99-110
Hemodialysis Vascular Access Dysfunction: From Pathophysiology to Novel Therapies
Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis population at a cost of over USD 1 billion per annum. Most hemodialysis grafts fail due to a venous stenosis (venous neointimal hyperplasia) which then results in thrombosis of the graft. Despite the magnitude of the clinical problem there are currently no effective therapies for this condition. The current review (a) describes the pathogenesis and pathology of venous stenosis in dialysis access grafts and (b) discusses the development and application of novel therapeutic interventions for this difficult clinical problem. Special emphasis is laid on the fact that PTFE dialysis access grafts could be the ideal clinical model for testing out novel local therapies to block neointimal hyperplasia.